3 SUMMARY Global loss of DNA methylation and CpG island (CGI) hypermethylation are regarded as key epigenomic aberrations in cancer. Global loss manifests itself in partially methylated domains (PMDs) which can extend up to megabases. However, the distribution of PMDs within and between tumor types, and their effects on key functional genomic elements including CGIs are poorly defined. Using whole genome bisulfite sequencing (WGBS) of breast cancers, we comprehensively show that loss of methylation in PMDs occurs in a large fraction of the genome and represents the prime source of variation in DNA methylation. PMDs are hypervariable in methylation level, size and distribution, and display elevated mutation rates. They impose intermediate DNA methylation levels incognizant of functional genomic elements including CGIs, underpinning a CGI methylator phenotype (CIMP). However, significant repression effects on cancer-genes are negligible as tumor suppressor genes are generally excluded from PMDs. The genomic distribution of PMDs reports tissue-of-origin of different cancers and may represent tissuespecific 'silent' regions of the genome, which tolerate instability at the epigenetic, transcriptomic and genetic level.
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in primary tumors is hitherto unknown. A major limitation of most DNA methylation studies is that only a small subset of CpGs are interrogated. This prevents accurate determination of the extent and location of PMDs. Few samples of a certain tissue/tumor have typically been analyzed using whole-genome bisulfite sequencing (WGBS). Thus, observations cannot be extrapolated to individual cancer types, let alone generalized to other cancers. Here, we analyzed DNA methylation profiles of 30 primary breast tumors at high resolution through WGBSsThis allowed us to, and delineate PMD characteristics in detail. We show that PMDs define (breast) cancer methylomes and are linked to other key epigenetic aberrations such as CGI hypermethylation.
RESULTS

Primary breast tumors display variable loss of DNA methylation
To study breast cancer epigenomes we performed WGBS encompassing~95% of annotated CpGs (Suppl. Fig. 1A , Suppl. Table 1 ). For 25/30 and 24/30 of these tumors we previously analyzed their full genomes 14, 15 and transcriptomes 16 , respectively. Of the 30 tumors, 25 and 5 are ER-positive and ER-negative, respectively (Suppl. Fig. 1B ).
To globally inspect aberrations in DNA methylation patterns we generated genome-wide and chromosome-wide methylome maps by displaying mean methylation in consecutive tiles of 10 kb (see Methods). These maps revealed extensive inter-tumor variation at genome-wide scale ( Fig. 1A) , that lacked obvious association with ER-status (p=0.15, t-test, Suppl. Fig. 2A ). At chromosome level, we observed stably hypermethylated regions next to regions that were hypomethylated to various extents and across tumors (Fig. 1B) . Chromosomes 1 and X were exceptionally prone to methylation loss. At megabase scale (Fig. 1C ) DNA methylation profiles showed that the widespread loss of methylation occurred in block-like structures previously defined as PMDs 2 . Across primary breast tumor samples, DNA methylation levels and genomic sizes of PMDs differ extensively between tumors and PMDs do appear as separate units in some tumors and as merged or extended in others, underscoring the high variation with which methylation loss occurs. Despite this variation, however, we observed common PMD boundaries as well.
Given the variation between tumors, we asked whether the patterns of methylation loss were associated with distribution of copy-number variations (CNVs) throughout the genome. We found no evidence for such association (Pearson R=0. 17 ), although we noticed that chromosomes with the most pronounced loss of methylation (chr1, chrX, chr8-p) frequently contained amplifications (Suppl. Fig. 1C ). Next, we asked whether loss of methylation was associated with aberrant expression of genes involved in writing, erasing, or reading the 5-methylcytosine modification. However, we found no such correlation (Suppl. Fig. 1D ).
To provide a reference for the observed patterns of methylation loss we compared WGBS profiles of primary breast tumors to that of 72 normal tissues (WGBS profiles from Roadmap Epigenomics Project and 10 , Suppl. Fig. 2A,B ). In sharp contrast to breast cancer, most normal tissues were almost fully hypermethylated (except for pancreas and skin), with heart, thymus, embryonic stem cell(-derived), induced pluripotent stem cells and brain having the highest levels of methylation. Importantly, inter-tissue variation was much lower as compared to breast tumors (p < 2.2e-16, MWU-test on standard deviations). Thus, breast tumors show widespread loss of DNA methylation in PMDs, and the extent and patterns appear to be hypervariable between tumor samples. In line with this, principal component analysis confirmed that methylation inside PMDs is the primary source of variation across full-genome breast cancer DNA methylation profiles ( Fig. 1D ): the first principal component (PC1) is strongly associated with mean PMD methylation (p=6.8e-07). The second-largest source of variation, PC2, is associated with ER status (p=1.9e-06, Fig. 1D ), while successive PCs were not significantly associated with any clinicopathological feature. It should be noted that with 30 tumors only very strong associations can achieve statistical significance. Taken together, breast tumor whole-genome DNA methylation profiles reveal global loss of methylation due to PMDs, the extent of which is hypervariable across tumors and represent the major source of variation between tumors.
Distribution and characteristics of breast cancer PMDs
We set out to further characterize breast cancer PMDs and their variation (see Methods: data access). The genome fraction covered by PMDs varies greatly across our WGBS cohort of 30 tumors, ranging between 10% and 50% across tumors, covering 32% of the genome on average 6 ( Fig. 2A ). We define 'PMD frequency' as the number of tumors in which a PMD is detected. A PMD frequency of 30 (PMDs common to all 30 cases) occurs in only a very small fraction of the genome (2%), while a PMD frequency of 1 (representing the union of all PMDs from 30 cases) involves 70.2% of the genome (Fig. 2B ). We tested to which extent PMD distribution is random, by counting PMD borders in 30-kb genomic tiles (Fig. 2C ). Randomly shuffled PMDs yield a normal distribution centered at a PMD frequency of four. In contrast, observed PMDs show a skewed distribution: the mode was for a PMD frequency of 0 suggesting that many tiles (23,492, 25%) do not coincide with any PMD borders. The majority of tiles (62%) had a low PMD border frequency (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . The tail represents low numbers of tiles with up to maximal PMD frequency of 30. We conclude that PMD distribution is not random: part of the genome appears not to tolerate PMDs while PMDs occur in a large fraction of the genome with varying frequencies.
PMDs have been shown to coincide with lamin-associated domains (LADs) 3, 4 : large repressive domains that preferentially locate to the nuclear periphery 17 . LADs are characterized by low gene density and late replication 17, 18 . Accordingly we found that PMDs show reduced gene densities Fig. 2D ) and have a low frequency of (Hi-C) 3D loops 19 , an indicator of lower levels of transcription. Finally, we observed a local increase in binding of the transcription factor CTCF at the borders of PMDs ( Fig. 2D ) as shown in previous reports 3, 17, [20] [21] [22] .
We previously analyzed the full transcriptomes (RNA-seq) in a breast cancer cohort of 266 cases 16 from which our WGBS cohort is a subset. We determined the mean expression of genes as a function of PMD frequency. Genes inside PMDs are expressed at consistently lower levels than genes outside of PMDs ( Fig. 2F , p < 2.2e-16, t-test), with a tendency towards lower expression in highly-frequent PMDs (p < 2.2e-16, linear regression). Given the variable nature of DNA methylation patterns of PMDs, we also determined the variation in gene expression as a function of PMD frequency and found higher variation for genes inside PMDs ( Fig. 2F , p < 2.2e-16, MWU-test). Even when restricting this analysis to only the subset of 24 overlapping cases from the transcriptome and WGBS cohort we observed the same trends, with similar statistical significance (Suppl. Fig. 3B , p < 2.2e-16, t-test for expression; p < 2.2e-16, MWU-test for variation). Given the observed variability of DNA methylation and gene expression inside PMDs, we asked whether genetic stability, i.e. the number of somatic mutations, was also altered within PMDs. In our cohort of 560 full breast cancer genomes 14 , substitutions, insertions, and deletions occur more frequently within than outside PMDs, with a clear increase in highly frequent PMDs (p < 2.2e-16 for each mutation type, logistic regression, Fig. 2G ). In contrast, rearrangements are more abundant outside of PMDs (p < 2.2e-16, logistic regression), in keeping with the hypothesis that regions with higher transcriptional activity are more susceptible to translocations 23 . As above, a restrictive analysis of only the 25 overlapping cases from the full genomes and WGBS cohorts revealed the same trends except for insertions (p < 2.2e-16 (substitutions); p = 0.362 (insertions), p = 1.7e-05 (deletions), p = 1.1e-09 (rearrangements), logistic regressions, Suppl. Fig. 3C ). Taken together, breast cancer PMDs share key features of PMDs including low gene density, low gene expression, and colocalization with LADs, suggesting that they reside in the 'B' (inactive) compartment of the genome 24 . Importantly, in addition to epigenomic instability, breast cancer PMDs also tolerate transcriptomic variability and genomic instability.
Relationship between CpG island methylation and PMDs in breast cancer
To determine how PMDs affect methylation of functional genomic elements we accordingly stratified all CpGs from all tumors and assessed the methylation distribution in these elements ( Fig. 2H ). We found that the normally observed near-binary methylation distribution is lost inside PMDs; the hypermethylated bulk of the genome and hypomethylated CGIs/promoters acquire intermediate levels of DNA methylation inside PMDs. DNA methylation deposition inside PMDs thus appears incognizant of genomic elements, resulting in intermediate methylation levels regardless of the genomic elements' functions. Among all elements, the effect of incognizant DNA methylation deposition is most prominent for CGIs as they undergo the largest change departing from a strictly hypomethylated state. This has been described also as focal hypermethylation inside PMDs 3 .
We further focused on methylation levels of CGIs. When indiviual PMDs are regarded, CGIs inside of them lose their strictly hypomethylated state and become more methylated to a degree that varies between tumors ( Concurrent hypermethylation of CGIs in cancer has been termed CIMP 25 , and in breast cancer this phenomenon has been termed B-CIMP 26-28 . To determine whether CIMP is directly related to PMD variation we defined B-CIMP as the fraction of CGIs that are hypermethylated (>30% methylated), and determined its association with the fraction of CGIs inside PMDs. Regression analysis (see Methods) showed that this association is highly significant (Fig. 3D, p=2 .1e-08, R 2 =0.51, n=30). The fraction of hypermethylated CGIs is generally higher than the fraction of hypermethylated CGIs in PMDs, suggesting that CGI hypermethylation is not solely dependent on PMD occurrence. However, CGI methylation levels outside PMDs are far more stable than inside PMDs (Fig. 3E ), which likely represents an invariably methylated set of CGIs (Suppl. We applied the same regression analysis to other tumor types (TCGA, 29 , Fig. 3F ). Although sample sizes were small, we found significant CIMP-PMD associations for lung adenocarcinoma (LUAD), rectum adenocarcinoma (READ), uterine corpus endometrial carcinoma (UCEC) and bladder urothelial carcinoma (BLCA). We did not find significant associations for Burkitt's lymphoma (BL), lung squamous cell carcinoma (LUSC), follicular lymphoma (FL), and glioblastoma (GBM), even though G-CIMP has been previously described 30 . Taken together, we conclude that PMD occurrence is an important determinant for CIMP.
PMD demethylation effects on gene expression
To assess whether widespread hypermethylation of CGI-promoters within PMDs instigates gene repression we analyzed expression as a function of gene location inside or outside of PMDs.
Overall, CGI-promoter genes showed a mild but significant downregulation when inside PMDs (p=4.5e-12, t-test), while strong downregulation was specifically restricted to low-frequency PMDs (Fig. 3G ). For non-CGI-promoter genes this trend was very weak or absent (Suppl. Fig.   9 4A). As healthy controls were not included in transcriptome analysis of our cohort 16 we used gene expression (RNA-seq) profiles from breast tumors (769) and normal controls (88) from TCGA. Similar to our cohort (see Fig. 2F ) we found that overall gene expression for the TCGA tumors is lower inside PMDs, with lowest expression for genes inside high-frequent PMDs (Fig.   3H , p < 2.2e-16, linear regression). However, the expression of genes in tumor PMDs is very similar to healthy control samples (p = 0.807, linear regression). To analyze this in more detail we selected normal/tumor matched pairs (i.e. from the same individuals, n=86) and analyzed the fold change over the different PMD frequencies ( Fig. 3I ). As in our cohort, downregulation is restricted to genes with low PMD-frequency (p < 2.2e-16 for PMD frequency 1-3, linear regression). No obvious changes occur in high-frequency PMD genes, nor in non-CGI-promoter genes (Suppl. Fig. 4B ). Taken together, widespread cancer-associated repression of all genes inside PMDs is limited: downregulation is restricted to low-frequency (i.e. the more variable)
PMDs and affects only CGI-promoter genes, which undergo widespread hypermethylation inside PMDs.
Given the widely accepted model of hypermethylated promoter-CGIs causing repression of tumor suppressor genes (TSGs) we determined whether breast cancer PMDs overlap with these genes to instigate such repression. For non-TSGs as a reference we found that 64% (14,037) are located outside of PMDs ( Fig. 3J ), while 36% are located inside, (see also Fig. 2E Similarly, from our previously identified set of genes containing breast cancer driver mutations 14 : 86/93 (92%) were located outside of PMDs (p=2.0e-11, hypergeometric test). Alltoghether, only 31 breast cancer-mutated genes were not excluded from PMDs. We assessed whether these genes are downregulated in tumors when inside PMDs. 24/31 (74%) genes were downregulated (Suppl. Fig. 5A,B) , and an overall negative correlation between CGI-promoter methylation and expression was evident (Suppl. Fig. 5C ). For 16 out of these 24 genes we confirmed that significant downregulation also takes place in cancer relative to normal in an independent breast cancer expression dataset (TCGA, Suppl. Fig. 5D and data not shown). Among the downregulated genes in PMDs are EGFR (epidermal growth factor receptor) and PDGFRA (platelet-derived growth factor receptor α) that have tumor promoting mutations (Suppl. Fig.   5A ,B,C). Paradoxically, both genes are significantly downregulated in our as well as the TCGA breast cancer dataset (Suppl. Fig. 5D ). Taken together, despite the large number of hypermethylated CpG islands inside breast cancer PMDs (13,013 CGIs; 47%, Suppl. Fig. 4C ), these CGIs do not generally co-occur with TSGs and other breast cancer-relevant genes.
Repression of these genes through classical promoter-hypermethylation in PMDs does not occur at large scale, and is likely limited to a few genes.
We next identified genes that are downregulated when inside PMDs regardless of any documented TSG function or mutation in breast cancer. 400 genes were downregulated at least 2.5 log2-fold (Suppl. Table 3 ). Gene set enrichment analysis showed that these genes were involved in processes such as signaling and adhesion (Suppl. Fig. 6A ). In addition, there is a Stratification of tumors according to low and high median expression of the 400 PMDdownregulated genes revealed significant differences in overall survival of the corresponding patients (p=2.6e-03, chi-square test, Suppl. Fig. 6C ), suggesting clinical significance of PMDassociated gene repression. Taken together, downregulation of genes inside PMDs occurs rarely and is restricted to low-frequency PMDs. However, these rare cases include genes relevant to breast cancer given the overlap with previously identified luminal B breast cancer-relevant genes and differential overall survival.
PMDs are not unique to cancers, but reduced DNA methylation in PMDs is a feature of many cancers
To assess the generality of PMD occurrence in cancer, we extended our analysis to other cancer types and normal tissues. We performed PMD detection in a total of 134 WGBS profiles (57 tumors from TCGA, 29 and 77 normal tissues from the Roadmap Epigenomics Project and 5 ).
PMDs are detectable in virtually all tumors, but also in 30% of normal tissues ( the highest of all tested tumors, while hypermethylation levels in lung adenocarcinoma/squamous cell carcinoma (LUAD/LUSC) were slightly lower than in other tumors. Possibly, these differences are linked to tumor cellularity of the samples. In two glioblastoma multiforme tumors, CGI hypermethylation was not restricted to PMDs, which is suggestive of inaccurate PMD detection due to high methylation inside glioblastoma PMDs (see Fig. 4B ). Importantly, these results extend the observed tendency of CGI hypermethylation inside PMDs to other tumors.
Lastly, to assess whether the distribution of tumor PMDs reflects tissue of origin we scored the presence of PMDs in genomic tiles of 30 kb and subsequently clustered the resulting binary profiles. The analysis showed that the majority of tumors of the same type clustered together, although not fully accurately ( Fig. 4C ), suggesting that the genomic distribution of PMDs is linked to tissue of origin. Thus, even though methylation levels of PMDs are independent of tissue-of-origin ( Fig. 4B ), the distribution of PMDs associates with tissue of origin, likely reflecting differences in the genomic parts that tolerate PMDs.
DISCUSSION
In this study we analyzed breast cancer DNA methylation profiles to high resolution. The main feature of breast cancer epigenomes is the extensive loss of methylation in PMDs and their hypervariability. Directly linked to this is the concurrent CGI hypermethylation, for which PMDs appear to be a major driver or even causal. Although various features of PMDs have been described before, our study is the first to include a larger WGBS cohort from one tumor type, while integrating sparse WGBS data from other tumor types. PMDs may be regarded as tissuetype-specific inactive constituents of the genome: the distribution shows tissue-of-origin specificity, gene expression inside PMDs is low and they are late replicating. Inside PMDs the accumulation of breast cancer mutations is higher than outside of them. The resulting domainlike fluctuation in mutation density is likely related to the fluctuating mutational density along the genome in cancer cells observed by others 32-34 . The phenomena observed in breast cancer extend to tumors of at least 10 additional tissue types underscoring the generality of our findings.
We conclude that loss of methylation in PMDs and concurrent CGI hypermethylation is a general hallmark of most tumor types with the exception of AMLs (data not shown).
The phenomena that we describe for breast cancer have remained elusive in genome-scale studies that only assessed subsets of the CpGs; the sparsity of included CpGs does not allow accurate PMD detection. Typical analysis strategies include tumor stratification by clustering of the most highly variable CpGs which at least in our breast cancer cohort are located in PMDs. In effect such approaches are biased towards CGIs due to their design and consequently, the hypermethylation groups represent tumors in which PMDs are highly abundant (e.g. 30,35-43 ). It is very likely that for some tumor types hypermethylation groups associate with clinicopathological features, amongst which a positive association with tumor cellularity is recurrent 36, [40] [41] [42] . This suggests that PMDs are more pronounced in tumor cells than in the non-tumor tissue of a cancer sample. This makes hypermethylated CGIs useful diagnostic markers but less likely informative as prognostic markers informing about tumor state, progression and outcome.
Since PMDs are domains in which instability at the genetic, epigenetic, and transcriptome level is tolerated, they may provide plasticity that is beneficial for the heterogeneity of tumor cells. Tables containing CpG methylation 
METHODS
Data access
Sample selection, pathology review and clinical data collection
Sample selection, pathology review and clinical data collection for this study has been described in 14 .
Processing of whole-genome bisulfite sequencing data
WGBS library preparation, read mapping, and methylation calling was done as described before 44 . The genome build used for mapping of bisulfite sequencing reads, and throughout this study was hg19 (GRCh37).
Principal component analysis of WGBS data
For principal component analysis (PCA) of WGBS profiles, CpGs with coverage of at least 10 were used. Subsequently, the top 5% most variable CpGs were selected. We used the FactoMineR package 45 for R to perform PCA and to determine association of principal components with clinicopathological features.
Detection of PMDs
Detection of partially methylated domains (PMDs) in all methylation profiles throughout this study was done using the MethylSeekR package for R 46 . Before PMD calling, CpGs overlapping common SNPs (dbSNP build 137) were removed. The alpha distribution 46 was used to determine whether PMDs were present at all, along with visual inspection of WGBS profiles. After PMD calling, the resulting PMDs were further filtered by removing regions overlapping with centromers (undetermined sequence content).
Mean methylation in PMDs and genomic tiles
Wherever mean methylation values from WGBS were calculated in regions containing multiple CpGs, the 'weighted methylation level' 47 
Clustering on PMD distribution
For each sample, the presence of PMDs was binary scored (0 or 1) in genomic tiles of 5 kb.
Based on these binary profiles, a distance matrix was calculated using [1-Jaccard] as a distance metric, which was used in hierarchical clustering using complete linkage. containing breast cancer driver mutations were determined using the list of 93 driver genes as published previously by us 14 .
Tumor suppressor genes and driver mutations
CIMP
To determine the association between B-CIMP (fraction of CGIs that are hypermethylated, >30% methylated) and PMD occurrence we used beta-regression using the 'betareg' package in R 48 .
Survival analysis
Survival analysis of patient groups stratified by expression of genes downregulated in PMDs. For each tumor sample of our breast cancer transcriptome cohort (n=266, 16 ), the median expression of all PMD-downregulated genes (Suppl. Table 3 ) was calculated. The obtained distribution of these medians was used to stratify patient groups, using a two-way split over the median of this distribution. Overall survival analysis using these groups was done using the 'survival' package in R, with chi-square significance testing. Each dot represents one tumor sample. Linear regression was used to determine the variation explained (R 2 ) and the p-value of the association. Expression data was taken from our previous work 16 .
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